Real-world data reveals how melanoma patients fare on two leading pre-surgery drug combos
NCT ID NCT07091695
First seen Nov 12, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two drug combinations given before surgery: nivolumab+relatlimab and nivolumab+ipilimumab. The goal was to understand patient characteristics, treatment patterns, and outcomes like survival and side effects in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States
Conditions
Explore the condition pages connected to this study.